EDAP TMS

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EDAP TMS reports Q1 revenue growth and FDA breakthrough designation

EDAP TMS reported solid revenue growth in Q1 2024, driven by strong international placements and advancements in Focal One technology. While facing financial challenges, the company is strategically positioned to benefit from the expanding HIFU market and upcoming regulatory milestones. Opportunities lie in market expansion, new study data releases, and continued engagement with regulatory bodies.

EDAP TMS reports strong Q2 earnings, poised for market expansion

EDAP TMS delivered robust performance in Q2 2024, driven by revenue growth and advancements in key medical programs.
While facing challenges in profitability and expenses, the company is strategically positioned to capitalize on market opportunities.
Investments in research, management, and clinical trials signal a proactive approach towards sustainable growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

EDAP TMS S.A. (NASDAQ:EDAP ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants John Fraunces - LifeSci Advisors Ryan Rhodes - CEO Ken Mobeck - CFO, US Subsidiary Conference Call Participants Michael Sarcone - Jefferies Sean Lee - H.C.

EDAP TMS S.A. (EDAP) Q3 2023 Earnings Call Transcript

- Strong Q3 2023 U.S. Focal One ® HIFU procedure growth of +150% year-over-year - - Record nine months HIFU revenues reflecting growing demand - - Two additional Focal One systems already placed in the fourth quarter - - Announces immunotherapy clinical research collaboration with Mount Sinai, Department of Urology - - Company to host conference call and webcast today, Thursday, November 9 th at 8:30 am EDT - LYON, France, November 9, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, reported today unaudited financial results for the third quarter ending September 30, 2023. “We continue to see stronger awareness and acceptance of focal therapy as a necessity in the management and treatment of prostate cancer,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS.

EDAP Announces Third Quarter 2023 Financial Results

LYON, France, November 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies London Healthcare Conference, which is being held November 14-16, 2023, in London.

EDAP to Present at the Jefferies London Healthcare Conference

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU's total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up 85% (YoY). EDAP's share price has declined 21.50% YoY and is trading almost 50% below its 52-week-high.

EDAP: Expecting Commercial Success In Prostate Cancer With Pipeline Expansion

Company to host conference call and webcast on Thursday, November 9 th at 8:30am EDT LYON, France, October 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30th, 2023, before the markets open on Thursday, November 9th, 2023. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer and Ken Mobeck, Chief Financial Officer of the U.S. subsidiary.

EDAP TMS SA to Announce Third Quarter 2023 Financial Results on November 9, 2023

EDAP TMS S.A. is a French developer of minimally invasive medical devices for urological diseases. The company operates in three segments: High Intensity Focused Ultrasound, Extracorporeal ShockWave Lithotripsy, and Distribution Services. High Intensity Focused Ultrasound is gaining traction as a treatment for prostate cancer and has potential applications in rectal endometriosis.

EDAP: French Company And A Solid Revenue Generator In Its Niche

LYON, France, September 6, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the upcoming Morgan Stanley 21st Annual Global Healthcare Conference and the H.C. Wainwright 25th Annual Global Investment Conference, both being held September 11-13, 2023, in New York City.

EDAP to Present at Morgan Stanley Annual Global Healthcare Conference and the H.C. Wainwright Annual Global Investment Conference

EDAP TMS S.A. (NASDAQ:EDAP ) Q2 2023 Earnings Conference Call August 24, 2023 8:30 AM ET Company Participants John Fraunces - Managing Director of LifeSci Advisors, LLC Ryan Rhodes - CEO Ken Mobeck - CFO, U.S. Subsidiary Francois Dietsch - CFO Conference Call Participants Michael Sarcone - Jefferies Frank Takkinen - Lake Street Capital Markets Jason Bednar - Piper Sandler Swayampakula Ramakanth - H.C.

EDAP TMS S.A. (EDAP) Q2 2023 Earnings Call Transcript

- Record second quarter and first half revenue s of EUR 14.3 million (USD 15 .5 million) and EUR 29.1 million (USD 31.5 million), respectively -

EDAP Announces Second Quarter 2023 Financial Results

- Company to host conference call and webcast on Thur sday, August 24 th at 8:30 am EDT -

EDAP TMS SA to Announce Second Quarter 2023 Financial Results on August 24, 2023

LYON, France, July 26, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it has received reimbursement approval in Switzerland for the use of High-Intensity Focused Ultrasound (HIFU) in the treatment of prostate cancer. This reimbursement took effect on July 1, 2023.

EDAP Announces Reimbursement Approval in Switzerland for the Use of High-Intensity Focused Ultrasound (HIFU) in the Treatment of Prostate Cancer

EDAP TMS S.A. shares have pushed lower in H2 FY'23, presenting an opportunity to add on weakness. EDAP's Q1 revenues were up 13.8% YoY, with HIFU sales up around 40% YoY. On examination, sentiment and positioning remains bullish in the stock based on market and options-generated data.

EDAP: Reiterate Buy After Multiple Investment Updates

LYON, France, May 24, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Healthcare Conference, which is being held June 7-9, 2023, in New York City.

EDAP to Present at the Jefferies Healthcare Conference

Start Time: 08:30 January 1, 0000 9:10 AM ET EDAP TMS S.A. (NASDAQ:EDAP ) Q1 2023 Earnings Conference Call May 17, 2023, 08:30 AM ET Company Participants Ryan Rhodes - CEO Ken Mobeck - CFO, U.S. Subsidiary Francois Dietsch - CFO John Fraunces - Managing Director of Life Advisors Conference Call Participants Joseph Downing - Piper Sandler Michael Sarcone - Jefferies Sean Lee - H.C.

EDAP TMS S.A. (EDAP) Q1 2023 Earnings Call Transcript

- Record first quarter revenue - - Positive results from two studies reconfirm safety and efficacy of Focal One - - Company to host conference call and webcast today, Wednesday, May 17 th at 8:30 am EDT - LYON, France, May 17, 2023 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today unaudited financial results for the first quarter ended March 31, 2023. “After achieving record results in the fourth quarter of 2022, we continued to see growing demand through the first quarter of 2023, with our strongest Q1 revenue performance on record,” said Ryan Rhodes, Chief Executive Officer of EDAP.

EDAP Announces First Quarter 2023 Financial Results

- Company to host conference call and webcast on Wednesday, May 1 7 th at 8:30 am EDT - LYON, France, May 3, 2023 - EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31st, 2023 before the markets open on Wednesday, May 17th, 2023. An accompanying conference call and webcast will be hosted by Ryan Rhodes, Chief Executive Officer, François Dietsch, Chief Financial Officer, and Ken Mobeck, Chief Financial Officer of the U.S. Subsidiary.

EDAP to Announce First Quarter 2023 Financial Results on May 17, 2023

Meeting to Showcase EDAP's Focal One ® Robotic High Intensity Focused Ultrasound (HIFU) Platform for the Management of Prostate Cancer LYON, France, April 21, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the Company will be showcasing its Focal One® Robotic High Intensity Focused Ultrasound (HIFU) platform at the upcoming Annual Meeting of the American Urological Association (AUA), the largest gathering of urologists worldwide, which will be held April 28th through May 1st in Chicago, IL. The Company will be having its largest presence ever at this year's AUA meeting.

EDAP Announces Major Presence at Upcoming Annual Meeting of the American Urological Association (AUA)

EDAP: Building Momentum Around HIFU, Calling For Strong Revenue Growth

Leading Center Demonstrates Focal HIFU as a Tool in The Management of Prostate Cancer

EDAP Announces Live Procedure Broadcast of Focal One High Intensity Focused Ultrasound (HIFU) to Global Clinical Audience

Allows for market launch of the only micro - ultrasound platform for precision prostate biopsies

EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan

EDAP TMS S.A. (NASDAQ:EDAP ) Q4 2022 Results Conference Call March 30, 2023 8:30 AM ET Company Participants John Fraunces - Managing Director of Life Advisors Marc Oczachowski - Chief Executive Officer and Chairman of the Board Ryan Rhodes - Chief Executive Officer of EWS Francois Dietsch - CFO Conference Call Participants Michael Sarcone - Jefferies Frank Takkinen - Lake Street Capital Markets Swayampakula Ramakanth - H.C.

EDAP TMS S.A. (EDAP) Q4 2022 Earnings Call Transcript

LYON, France, March 30, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), a global leader in robotic energy-based therapies, announced today unaudited financial results for the fourth quarter and full-year 2022 and announced a change in its leadership, effective May 1, 2023.

EDAP Reports Record Fourth Quarter and Full-Year 2022 Results and Announces Leadership Succession Plan to Develop Global Group Strategy

Results demonstrate salvage treatment free survival rate (STFS) at 30 months of 90.1% in the HIFU-treated arm versus 86.8% in patients who underwent radical prostatectomy (RP)

EDAP Presents Positive Results from Non-Inferiority Study Comparing Outcomes of Focal One HIFU Versus Radical Prostatectomy at EAU23

LYON, France, March 9, 2023 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the fourth quarter and full-year ended December 31, 2022, before the markets open on Thursday, March 30th, 2023.

EDAP to Announce Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 30th

Record f ull-year 2022 total preliminary unaudited revenue of €55.1 million ($58 .0 million) represents an increase of 25. 1 % over full-year 2021, driven by 58.1% HIFU growth

News for EDAP TMS Stock (EDAP)